Company Quick10K Filing
Immunomedics
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 192 $2,456
10-Q 2019-10-30 Quarter: 2019-09-30
10-Q 2019-08-07 Quarter: 2019-06-30
10-Q 2019-05-09 Quarter: 2019-03-31
10-Q 2018-11-07 Quarter: 2018-09-30
10-K 2018-08-23 Annual: 2018-06-30
10-Q 2018-05-09 Quarter: 2018-03-31
10-Q 2018-02-08 Quarter: 2017-12-31
10-Q 2017-11-09 Quarter: 2017-09-30
10-K 2017-08-16 Annual: 2017-06-30
10-Q 2017-05-10 Quarter: 2017-03-31
10-Q 2017-02-09 Quarter: 2016-12-31
10-Q 2016-11-02 Quarter: 2016-09-30
10-K 2016-08-18 Annual: 2016-06-30
10-Q 2016-05-04 Quarter: 2016-03-31
10-Q 2016-02-03 Quarter: 2015-12-31
10-Q 2015-11-04 Quarter: 2015-09-30
10-K 2015-08-19 Annual: 2015-06-30
10-Q 2015-05-06 Quarter: 2015-03-31
10-Q 2015-02-04 Quarter: 2014-12-31
10-Q 2014-11-05 Quarter: 2014-09-30
10-K 2014-08-25 Annual: 2014-06-30
10-Q 2014-05-07 Quarter: 2014-03-31
10-Q 2014-02-10 Quarter: 2013-12-31
10-Q 2013-11-04 Quarter: 2013-09-30
10-K 2013-08-22 Annual: 2013-06-30
10-Q 2013-05-08 Quarter: 2013-03-31
10-Q 2013-02-07 Quarter: 2012-12-31
10-K 2012-08-23 Annual: 2012-06-30
10-Q 2012-05-08 Quarter: 2012-03-31
10-Q 2012-02-08 Quarter: 2011-12-31
10-Q 2011-11-04 Quarter: 2011-09-30
10-K 2011-08-24 Annual: 2011-06-30
10-Q 2011-05-10 Quarter: 2011-03-31
10-Q 2011-02-04 Quarter: 2010-12-31
10-Q 2010-11-04 Quarter: 2010-09-30
10-K 2010-08-26 Annual: 2010-06-30
10-Q 2010-05-10 Quarter: 2010-03-31
10-Q 2010-02-02 Quarter: 2009-12-31
8-K 2019-12-26 Other Events, Exhibits
8-K 2019-12-04 Enter Agreement, Other Events, Exhibits
8-K 2019-12-03 Other Events, Exhibits
8-K 2019-10-30 Earnings, Exhibits
8-K 2019-09-28 Other Events, Exhibits
8-K 2019-08-07 Earnings, Exhibits
8-K 2019-06-05 Shareholder Vote, Other Events
8-K 2019-05-28 Officers
8-K 2019-05-09 Earnings, Exhibits
8-K 2019-04-29 Enter Agreement, Other Events, Exhibits
8-K 2019-04-24 Officers, Other Events, Exhibits
8-K 2019-04-15 Amend Bylaw, Exhibits
8-K 2019-04-15 Other Events
8-K 2019-04-05 Enter Agreement, Other Events, Exhibits
8-K 2019-03-29 Enter Agreement, Exhibits
8-K 2019-03-13 Officers
8-K 2019-03-05 Officers, Other Events, Exhibits
8-K 2019-03-05 Officers
8-K 2019-02-22 Officers, Other Events, Exhibits
8-K 2019-02-11 Other Events, Exhibits
8-K 2019-02-04 Other Events
8-K 2019-01-17 Other Events, Exhibits
8-K 2019-01-15 Other Events
8-K 2018-12-20 Enter Agreement
8-K 2018-12-19 Enter Agreement, Other Events, Exhibits
8-K 2018-12-14 Amend Bylaw
8-K 2018-11-07 Earnings, Exhibits
8-K 2018-10-02 Enter Agreement, Sale of Shares
8-K 2018-09-24 Officers
8-K 2018-09-11 Enter Agreement, Other Events, Exhibits
8-K 2018-08-23 Earnings, Exhibits
8-K 2018-08-23 Officers
8-K 2018-07-18 Other Events, Exhibits
8-K 2018-07-06 Enter Agreement
8-K 2018-06-22 Other Events, Exhibits
8-K 2018-06-12 Enter Agreement, Other Events, Exhibits
8-K 2018-06-04 Other Events, Exhibits
8-K 2018-06-01 Regulation FD, Other Events, Exhibits
8-K 2018-05-09 Earnings, Exhibits
8-K 2018-04-13
8-K 2018-04-09 Enter Agreement, Officers, Exhibits
8-K 2018-04-04 Enter Agreement
8-K 2018-04-02 Shareholder Vote
8-K 2018-02-08 Earnings, Exhibits
8-K 2018-01-07 Enter Agreement, Sale of Shares, Exhibits

Immunomedics Financials

IMMU Metrics, Comps, Filings

Annual | Quarterly

Business

Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer. Our advanced proprietary technologies allow us to create humanized antibodies that can be used either alone in unlabeled or "naked" form, or conjugated with chemotherapeutics, cytokines or toxins. Our most advanced product candidate is sacituzumab govitecan ("IMMU-132"), an antibody-drug conjugate ("ADC") that has received Breakthrough Therapy Designation ("BTD") from the United States Food and Drug Administration (the "FDA") for the treatment of patients with metastatic triple-negative breast cancer ("mTNBC") who previously received at least two prior therapies for metastatic disease.

Our current focus is to commercialize sacituzumab govitecan as a third-line therapy for patients with mTNBC in the United States. On May 21, 2018 we submitted a Biologics License Application ("BLA") to the FDA for sacituzumab govitecan for the treatment of patients with mTNBC who have received at least two prior therapies for metastatic disease. On July 18, 2018 we received notification from the Food and Drug Administration ("FDA") that the BLA was accepted for filing and granted Priority Review with a PDUFA target action date of January 18, 2019. If approved, sacituzumab govitecan would be the first and only ADC approved for the treatment of mTNBC.

As of June 30, 2018, we had $638.8 million in cash, cash equivalents and marketable securities. On January 7, 2018, we announced that we sold tiered, sales-based royalty rights on global net sales of sacituzumab govitecan to RPI Finance Trust ("RPI") for $175.0 million. RPI also purchased $75.0 million of our common stock at $17.15 per share, which represented a more than 15% premium over the stock's 15-day trailing average closing price at that time. On June 15, 2018, we announced the closing of a public offering of 11,500,000 shares of our common stock at a price of $24.00 per share. On June 22, 2018, pursuant to the underwriter's full exercise of the over-allotment option, we closed the sale of an additional 1,725,000 shares of our common stock. The total net proceeds from the offering, including the exercise of the over-allotment option, were approximately $300 million, after deducting underwriting discounts and commissions and other offering expenses payable by us. We believe our projected financial resources are adequate to (i) support our next phase of growth as we focus on commercializing and developing sacituzumab govitecan in mTNBC, advanced urothelial cancer ("UC"), advanced ER+ BC and other indications of high medical need, (ii) further build our clinical, medical affairs, commercial and manufacturing infrastructure, (iii) begin to commercialize sacituzumab govitecan globally, and (iv) fund operations into 2021 or beyond assuming we meet our regulatory and commercial objectives. However, in case of regulatory delays, alterations to our commercial forecast, or other unforeseen events, we may require additional funding in 2021. Potential sources of funding in such a case could include (i) the entrance into potential development and commercial partnerships to advance and maximize our full pipeline for mTNBC and beyond in the United States and globally, and (ii) potential private and capital markets financing.


Valuation ($BB)

Market Cap, Enterprise Value

Balance Sheet ($BB)

Assets, Stockholders' Equity

Income Statement ($BB Annual)

Revenue, Gross Profit, Net Income

Cash Flow ($BB Annual)

Operating, Investing, Financing

Comps ($MM TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Neogen (NEOG) 4,151 46% 44.9 8% 721 61 416 193 60 91 4,095
Quidel (QDEL) 2,482 60% 22.8 8% 846 336 506 302 69 108 2,453
Immunomedics (IMMU) 2,456 0% -6.7 -72% 478 363 0 0 -344 -301 2,026
Myriad Genetics (MYGN) 2,016 0% 21.1 0% 1,563 474 851 0 5 102 2,157
Lantheus Holdings (LNTH) 1,112 51% 25.8 3% 390 298 347 177 13 49 1,255
Intellia Therapeutics (NTLA) 727 100% -8.1 -25% 352 76 37 37 -89 -84 678
Quotient (QTNT) 626 40% 1,004.8 -54% 193 215 29 12 -104 -89 -89,908
Meridian Bioscience (VIVO) 490 60% 11.8 8% 322 134 203 121 26 43 511
Oxford Immunotec Global (OXFD) 370 72% 1.9 56% 242 24 66 48 137 96 183
Trinity Biotech (TRIB) 235 0% 152 108 0 0 0 0 228
Oncocyte (OCX) 130 -5.8 -44% 38 4 0 0 -17 -16 94
Volitionrx (VNRX) 125 -6.7 -75% 23 6 0 0 -17 -16 109
Nymox Pharmaceutical (NYMX) 92 0% 8 1 0 0 0 0 92
Vermillion (VRML) 82 17% -5.2 -74% 18 5 4 1 -14 -13 67
Riot Blockchain (RIOT) 69 12% -1.8 -105% 31 5 8 1 -32 -29 53
Immucell (ICCC) 48 47% 141.5 -5% 39 10 12 6 -2 0 46
Celldex Therapeutics (CLDX) 38 0% 6.4 0% 142 33 5 0 0 3 18
Achieve Life Sciences (ACHV) 20 -0.6 -111% 15 3 0 0 -16 -16 9
Navidea Biopharmaceuticals (NAVB) 12 100% -0.6 -149% 8 5 1 1 -12 -12 7
Arca Biopharma (ABIO) 10 -0.1 -60% 10 1 0 0 -6 -6 0

Balance Sheet ($MM)2012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-30
Cash3341421005143639
Accounts Receivable1110100
Inventory0111010
PP&E3292924516
Assets39484710657163664
Accounts Payable11235525
Long-Term Debt
Liabilities7117110114221264
Stockholders' Equity323739-4-57-59401
Income Statement ($MM)2012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-30
Revenue33333232
Cost of Revenue
Gross Profit
R&D25293442535299
SG&A7791083043
Tax0000000
Net Income1-12-36-48-59-153-274
Cash Flow ($MM)2012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-30
Cash Operating5-6-31-39-48-62-134
Cash Investing-1-0-35-5346-7675
Cash Financing21531992169628